Ann: Update on PainChek Business Performance, page-123

right on with your analysis. I think it was slower than expected by holders, not so much the companies forecast. PCK was rolled out around the start of 2018, and the price dropped over 50% to less than 3 cents over nearly 1 year to April 2019. It was always slow and steady progress. What changed was the government grant which exploded the price, but then created an expectation that it was going to be high speed uptake from there. The price was at a low around 3 cents in April 2019, it is only 9 months since then.

In the grand scheme of things, getting the government grant this early is insane though the continuing the roll out is actually slow, and waiting on the price to multi bag towards 500mill or 1 billion market cap feels like a drainer.

By comparison look at ALC, that chart and market cap is very similiar and they have grown much larger revenues but with more volatility as well.
AVH also has a similar chart and went to the moon to 1 billion market cap, but they received FDA approval, to run from around 8 cents to 60 cents. Completely different company but it is clear that FDA is one major milestone that must be obtained to even get a change to to move towards 1 billion market cap.

The Australian market is tiny, and people possibly underestimate how small it is globally. It is a testing field for the app.